Rami Elghandour, Arcellx
Arcellx raises mega-round to put controllable CAR-T into the clinic
Arcellx claims to have the first controllable CAR-T ready for the clinic. Now they’ll have cash — a boatload of cash — to get it through.
The Gaithersburg, MD-based biotech announced Tuesday a $115 million Series C led by Samsara BioCapital and CAM Capital. Arcellx will use their first round, their first since they emerged from stealth with an $85 million Series B in 2019, to begin two Phase I trials for their reprogrammable CAR-Ts, while pushing a more traditional CAR-T for multiple myeloma into a pivotal study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
